
(IN BRIEF) Evotec SE has announced that Esperion Therapeutics has nominated an oral preclinical development candidate for primary sclerosing cholangitis (PSC), marking a major milestone in their collaboration. The PDC, developed through Evotec’s integrated small molecule discovery platform and Esperion’s … Read the full press release